Alpha 2.0
Login Register
» Authors » Marika Page

Marika Page

Explore the profile of Marika Page including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 8
Citations 23
Followers 0
Related Specialties
Endocrinology
Pathology
Orthopedics
Top 10 Co-Authors
Marie-Eve Robinson
Leanne M Ward
Frank Rauch
Khaldoun Koujok
Kevin Smit
Victor N Konji
Sasha Carsen
Jinhui Ma
Nasrin Khan
Nazih Shenouda
Published In
Bone Rep
J Endocr Soc
Calcif Tissue Int
JBMR Plus
Osteoporos Int
Affiliations
Soon will be listed here.
Recent Articles
1.
Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome
Abebe L, Phung K, Robinson M, Waldner R, Carsen S, Smit K, et al.
Bone Rep . 2024 Jan; 20:101725. PMID: 38229908
Cutaneous-skeletal hypophosphatemia syndrome (CSHS) is a rare bone disorder featuring fibroblast growth factor-23 (FGF23)-mediated hypophosphatemic rickets. We report a 2-year, 10-month-old girl with CSHS treated with burosumab, a novel human...
2.
Risk Factors Associated with Incident Vertebral Fractures in Steroid-treated Males with Duchenne Muscular Dystrophy
Phung K, McAdam L, Ma J, McMillan H, Jackowski S, Scharke M, et al.
J Clin Endocrinol Metab . 2023 Aug; 109(2):536-548. PMID: 37610420
Purpose: Prevention of fractures is an unmet need in glucocorticoid (GC)-treated Duchenne muscular dystrophy. This study explored factors associated with incident vertebral fractures (VFs) to inform future fracture prevention efforts....
3.
Canakinumab in addition to phosphate-binding and phosphaturia-inducing therapy were effective in achieving remission in a child with a large familial calcinotic tumour
Ochoa M, Jurencak R, Smit K, Carsen S, Sawyer S, Robinson M, et al.
Bone Rep . 2023 Jul; 19:101695. PMID: 37520934
We describe the clinical evolution of a patient with tumoral calcinosis due to a pathogenic variant in the gene presented with a large mass overlying her left hip associated complicated...
4.
From "" to "I CAN": Restoring wellness in a boy with severe osteochondritis dissecans through diagnostic precision combined with optimal medical, surgical and rehabilitation management
Ochoa M, Yang A, Kollias C, Bakir C, Carsen S, Lazier J, et al.
Bone Rep . 2023 Mar; 18:101663. PMID: 36950254
Osteochondritis dissecans (OCD) is a disease of the joints characterized by idiopathic focal subchondral lesions. Aggrecan, a proteoglycan encoded by the gene, is important for cartilage structure and function. We...
5.
Mitigating the Denosumab-Induced Rebound Phenomenon with Alternating Short- and Long-Acting Anti-resorptive Therapy in a Young Boy with Severe OI Type VI
Seale E, Molina M, Carsen S, Sheffield H, Koujok K, Robinson M, et al.
Calcif Tissue Int . 2023 Mar; 112(5):613-620. PMID: 36867194
Osteogenesis imperfecta (OI) type VI, a recessively inherited form of OI caused by mutations in SERPINF1, is a severe form distinguished by osteomalacia on bone histomorphometry. We describe a boy...
6.
Risk factors associated with prevalent vertebral fractures in Duchenne muscular dystrophy
Phung K, McAdam L, Ma J, McMillan H, Jackowski S, Scharke M, et al.
Osteoporos Int . 2022 Nov; 34(1):147-160. PMID: 36342539
Introduction: Fragility  fractures are frequent in DMD. The purpose of this study was to identify clinical factors associated with prevalent vertebral fractures (VF) in boys, teens/young adults with Duchenne muscular...
7.
Local Tumor Recurrence and Escape from Suppression of Bone Resorption With Denosumab Treatment in Two Adolescents With Giant Cell Tumors of Bone
Akel U, Robinson M, Werier J, Rampersaud R, Rakhra K, Johnston D, et al.
JBMR Plus . 2019 Nov; 3(9):e10196. PMID: 31667453
Giant cell tumors of bone (GCTB) may be difficult to resect because of size or location. We describe two adolescents who were treated with denosumab and followed for tumoral and...
8.
The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitor-Treated Chronic Myelogenous Leukemia
Lavoie D, Robinson M, Johnston D, Page M, Konji V, Rauch F, et al.
J Endocr Soc . 2019 Apr; 3(5):857-864. PMID: 30997443
Tyrosine kinase inhibitors (TKIs) have been linked to bone pain and linear growth attenuation in children with TKI-treated chronic myelogenous leukemia (CML). We describe the skeletal phenotype in an 11-year-old...